Cocrystal Pharma, Inc.
Develops novel antiviral drugs for influenza, coronaviruses, norovirus, and hepatitis C.
COCP | US
Overview
Corporate Details
- ISIN(s):
- US19188J4094
- LEI:
- Country:
- United States of America
- Address:
- 19805 N. CREEK PARKWAY, 98011 BOTHELL
- Website:
- https://www.cocrystalpharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that discovers and develops novel antiviral therapeutics for serious and chronic viral diseases. The company utilizes its proprietary structure-based drug design technologies and Nobel Prize-winning expertise to create antiviral drugs that target the viral replication process. Its development pipeline includes candidates for the treatment of influenza, coronaviruses (including SARS-CoV-2), norovirus, and hepatitis C. Key programs in its portfolio are at various stages of clinical development, including a Phase 2 trial for an influenza A inhibitor (CC-42344) and a Phase 1 trial for a pan-viral protease inhibitor (CDI-988) targeting norovirus and coronaviruses.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Cocrystal Pharma, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cocrystal Pharma, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cocrystal Pharma, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
